Media coverage about Assembly Biosciences (NASDAQ:ASMB) has been trending somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Assembly Biosciences earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.4205663824517 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Shares of Assembly Biosciences (ASMB) traded up 2.25% during midday trading on Monday, hitting $30.95. 28,098 shares of the company traded hands. Assembly Biosciences has a 52 week low of $6.74 and a 52 week high of $31.05. The stock has a 50 day moving average of $25.63 and a 200-day moving average of $23.89. The stock’s market capitalization is $537.42 million.
Several equities analysts have commented on ASMB shares. Chardan Capital started coverage on shares of Assembly Biosciences in a report on Tuesday, May 30th. They issued a “buy” rating and a $35.00 target price on the stock. BidaskClub raised shares of Assembly Biosciences from a “hold” rating to a “buy” rating in a report on Friday, August 18th. Finally, Zacks Investment Research lowered shares of Assembly Biosciences from a “hold” rating to a “sell” rating in a report on Monday, August 14th.
TRADEMARK VIOLATION WARNING: This piece of content was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://stocknewstimes.com/2017/09/18/assembly-biosciences-asmb-receives-media-impact-rating-of-0-11.html.
About Assembly Biosciences
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
Receive News & Ratings for Assembly Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.